• Evercore ISI maintains an "Outperform" rating for Walmart (NYSE:WMT), raising the price target to $111 from $110.
• Walmart partners with Abbott Laboratories to offer the Lingo continuous glucose monitor, expanding its healthcare offerings.
• The stock's current price of $107.05 reflects a slight decrease, but Evercore ISI's optimism suggests potential for growth.

Walmart (NYSE:WMT) is a leading global retailer known for its vast network of stores and e-commerce platforms. It offers a wide range of products, from groceries to electronics, and competes with other retail giants like Amazon and Target. On October 21, 2025, Evercore ISI maintained its "Outperform" rating for Walmart, with the stock priced at $107.05. The price target was raised to $111 from $110, indicating confidence in Walmart's growth prospects.

Walmart's recent partnership with Abbott Laboratories to offer the Lingo continuous glucose monitor over-the-counter is a strategic move. This product will be available in over 3,500 Walmart locations and online, enhancing accessibility to medical devices. This initiative aligns with Walmart's commitment to expanding its healthcare offerings, as highlighted by Axios.

The current stock price of $107.05 reflects a slight decrease of 0.63%, with fluctuations between $106.61 and $108.25 today. Despite this, Evercore ISI's raised price target suggests optimism about Walmart's future performance. The stock's 52-week range shows a high of $109.58 and a low of $79.81, indicating some volatility over the past year.

Walmart's market capitalization is approximately $853.49 billion, underscoring its significant presence in the retail sector. The trading volume of 8.6 million shares demonstrates active investor interest. As Walmart continues to innovate and expand its product offerings, it remains a key player in the competitive retail landscape.